DRKS00017588已完成不适用
Treatment Adjustment in commonly used Biologics for the treatment of moderate to severe chronic plaque psoriasis: a German real world retrospective study (TABU) - TAB
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 983
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Adult patients (between 18 and 65 years of age) whose primary indication for biologic therapy was moderate to severe plaque PsO having received a biologic for a minimum of 36 weeks with either Adalimumab, Guselkumab, Ixekizumab, Secukinumab or Ustekinumab.
- •Patients who received the induction doses of the biologic as per local label.
排除标准
- •- Patients having participated in interventional clinical trial(s) during the chart review time period
- •- Patients receiving biologics during pregnancy
- •- Patients stopping biologic therapy due to upfront planned surgeries
研究者
相似试验
进行中（未招募）
1 期
OPTIMAL - Individualized dosetitration of biological treatment in severe asthmaSevere asthmaMedDRA version: 21.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855EUCTR2020-003358-63-DKBispebjerg Hospital150
进行中（未招募）
不适用
Comparing the effects of infliximab and alpha interferon in the treatment of Behçet’s DiseaseBehçet diseaseMusculoskeletal DiseasesISRCTN49793874niversity of Liverpool79
尚未招募
Unknown
Pharmaceutical guidance for optimizing the use of asthma medicationsAsthmaRBR-9kkjvnjniversidade Federal do Rio Grande do Norte
招募中
不适用
ShorT spAce or incRease dosage of Biologics for rheumatoid arthritis patients with subclinical synOvitis detected by ultrAsound suppRess joint DestructioRheumatoid ArthritisJPRN-UMIN000036601Osaka city university, School of medicine100
招募中
不适用
Pharmaceutical-pharmacological interventions to improve drug therapy safety of inpatient carelow adherence, problems with drug application/use, patients' concerns regarding their drug therapyDRKS00026088Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Medizinische Klinik100